United States Patent 9,289,472: Scope, Claims, Exclusivity and Arimoclomol Patent Landscape
U.S. Patent No. 9,289,472 is a method-of-treatment patent covering the use of hydroxylamine derivatives, especially arimoclomol, to treat lysosomal storage diseases by increasing intracellular Hsp70 through amplified Hsp70 gene expression. The commercially important claim combination is arimoclomol, Niemann-Pick disease, and combination therapy with a substrate-reduction treatment such as miglustat.
The patent is strategically relevant to Miplyffa, the arimoclomol product approved by the U.S. Food and Drug Administration in 2024 for Niemann-Pick disease type C. The patent does not claim arimoclomol as a chemical composition. Its protection is directed to therapeutic use, disease categories, mechanism of action, and combinations with other treatments.[1][2]
What does U.S. Patent 9,289,472 protect?
The patent protects a treatment method having four core elements:
- A patient has a lysosomal storage disease.
- A hydroxylamine derivative is administered.
- The agent increases intracellular Hsp70 by amplifying Hsp70 gene expression.
- The treatment can be used alone or with specified treatment modalities.
Claim 1 establishes the broadest independent scope:
A method for treating a lysosomal storage disease by administering a hydroxylamine derivative capable of increasing intracellular Hsp70 through amplified Hsp70 gene expression.
The claim is functional rather than limited to a single named compound. It therefore seeks coverage of compounds that satisfy the specified biological mechanism, even if they are not expressly listed in the dependent claims.
Claim structure and commercial relevance
| Claim |
Subject matter |
Commercial significance |
| 1 |
Hydroxylamine derivative for lysosomal storage disease through Hsp70 gene-expression amplification |
Broadest method claim |
| 2 |
Curative or ameliorating treatment |
Broad therapeutic-use limitation |
| 3 |
Treatment before disease onset |
Prophylactic or presymptomatic use |
| 4 |
Bimoclomol or structural analogue |
Compound-class expansion |
| 5 |
Bimoclomol, arimoclomol, BRX-220, BRX-345 or BGP-15 |
Named compound group |
| 6 |
Arimoclomol |
Primary marketed-product claim |
| 7 |
BRX-345 |
Development-stage or alternative-product protection |
| 8 |
Eight named lysosomal storage diseases |
Disease-specific scope |
| 9 |
Niemann-Pick disease types A, B, C and D |
Core Niemann-Pick coverage |
| 10 |
Combination with ERT, pain relievers, corticosteroids, transplantation, substrate reduction, or Hsp70 |
Combination-treatment coverage |
| 11 |
Combination with enzyme replacement therapy |
Narrower combination claim |
| 12 |
ERT agents including imiglucerase, miglustat, agalsidase beta and agalsidase alpha |
Named co-therapy scope |
| 13 |
Hsp70 fragment or variant retaining at least 95% sequence identity |
Protein-combination coverage |
| 14 |
Recombinant Hsp70 |
Specific protein-combination claim |
How broad is claim 1 of U.S. Patent 9,289,472?
Claim 1 is broad in disease and compound class but narrow in mechanism. It is not limited to Niemann-Pick disease or arimoclomol. It reaches any lysosomal storage disease and any hydroxylamine derivative that meets the Hsp70 gene-expression limitation.
The main boundaries are:
- The agent must be a hydroxylamine derivative.
- The agent must increase intracellular Hsp70.
- The increase must result from amplifying Hsp70 gene expression.
- The use must treat a lysosomal storage disease.
- Administration must occur to an individual in need of treatment.
A hydroxylamine derivative that improves lysosomal function through a mechanism unrelated to Hsp70 gene expression would face a stronger non-infringement position under the literal wording of claim 1. The same is true for a compound that increases Hsp70 protein through stabilization, reduced degradation, or increased translation without amplifying Hsp70 gene expression.
The claim also raises potential interpretation issues. “Capable of increasing” may be assessed by the compound’s biological properties rather than by the accused product’s label. Evidence from cell assays, gene-expression studies, pharmacology data, and product development documents could become relevant in an infringement dispute.
Which compounds are covered by the patent?
The dependent claims name five hydroxylamine derivatives:
- Bimoclomol
- Arimoclomol
- BRX-220
- BRX-345
- BGP-15
Arimoclomol is the most commercially important compound. Claim 6 independently narrows the invention to arimoclomol while retaining all limitations of claim 1. A product containing arimoclomol would therefore need to avoid at least one element of claim 1 to avoid literal infringement of claim 6.
Claim 4 also covers bimoclomol and structural analogues. That language could reach compounds structurally related to bimoclomol, although the scope of “structural analogue” would depend on the patent’s specification, prosecution history, and claim-construction record. Claim 5 provides a closed list of named compounds and is narrower than claim 4 for compounds outside that list.
Arimoclomol and Miplyffa
The FDA approved Miplyffa, containing arimoclomol, on September 20, 2024, in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children at least 2 years old.[2] The approved combination maps closely to the patent’s claim architecture:
- Arimoclomol maps to claim 6.
- Niemann-Pick disease type C maps to claim 9.
- Miglustat is identified in claim 12.
- Miglustat is also a substrate-reduction therapy, corresponding to claim 10.
The patent’s broad claim 9 covers NPC types A through D, while the FDA-approved indication is limited to NPC. Patent scope is therefore broader than the current labeled indication.
What lysosomal storage diseases are covered?
Claim 8 identifies:
- Niemann-Pick disease
- Farber disease
- Krabbe disease
- Fabry disease
- Gaucher disease
- Sialidosis
- Metachromatic leukodystrophy
- Saposin deficiency
Claim 9 divides Niemann-Pick disease into types A, B, C and D.
The disease list covers disorders with different enzyme defects, lipid-storage profiles, and clinical manifestations. The claim set therefore attempts to protect a shared Hsp70-based therapeutic approach across otherwise heterogeneous diseases.
This breadth creates both commercial value and validity exposure. A broad disease claim may be challenged if prior art disclosed the same hydroxylamine derivative, Hsp70 induction, or treatment of a related lysosomal storage disorder. Enablement and written-description questions could focus on whether the specification supports the full disease list and the full range of hydroxylamine derivatives identified in claim 1.
What formulations are protected by U.S. Patent 9,289,472?
The claims supplied do not recite:
- A specific dosage form
- Capsule, tablet, liquid or injectable formulation
- Particle size
- Salt or crystalline form
- Excipient system
- Release profile
- Specific dose
- Pharmacokinetic target
- Manufacturing process
The patent is therefore not principally a formulation patent. It is a therapeutic-use patent.
A later arimoclomol formulation, solid-form, dosage, manufacturing, or pharmaceutical-composition patent could create additional barriers, but such rights would be separate from the claims supplied for U.S. Patent 9,289,472. A generic or follow-on manufacturer could potentially avoid formulation claims while still infringing the method claims if it markets arimoclomol for the claimed disease and mechanism.
How do the combination claims affect Miplyffa?
Claims 10 through 14 extend protection beyond arimoclomol monotherapy.
Claim 10 covers administration with at least one other treatment modality, including:
- Enzyme replacement therapy
- Pain relievers
- Corticosteroids
- Transplantation
- Substrate-reduction therapy
- Hsp70 protein
- Hsp70 fragments
- Hsp70 variants
Claim 11 narrows the combination to enzyme replacement therapy. Claim 12 identifies several specific agents, including miglustat, imiglucerase, agalsidase beta and agalsidase alpha.
The claim language presents a drafting issue: miglustat is listed under the claim’s “enzyme replacement therapy” group even though miglustat is generally classified pharmacologically as a substrate-reduction therapy. The presence of miglustat in the closed list gives it independent significance, but the relationship between claim 12 and the ERT limitation would depend on the specification and claim construction.
For Miplyffa, the most relevant combination theory is arimoclomol plus miglustat under claims 10 and 12. The FDA label directs use with miglustat, increasing the practical relevance of those claims.[2]
When does U.S. Patent 9,289,472 lose exclusivity?
The patent issued on March 22, 2016. The patent’s term is governed by the earliest effective nonprovisional filing date, applicable patent-term-adjustment provisions, and any terminal disclaimer. A reliable expiration date cannot be derived from the claims alone.
The expected commercial significance of the patent is its relationship to arimoclomol’s U.S. regulatory exclusivity. Miplyffa received orphan-drug approval for NPC. Orphan-drug exclusivity generally prevents FDA approval of the same drug for the same disease or condition for seven years from approval, subject to statutory exceptions.[2][3]
| Protection |
Subject |
Relevance |
| U.S. Patent 9,289,472 |
Method of treating lysosomal storage diseases with hydroxylamine derivatives |
Potentially covers arimoclomol use through the patent term |
| FDA orphan-drug exclusivity |
Arimoclomol for NPC |
Separate regulatory protection beginning with Miplyffa approval |
| FDA approval exclusivity |
Miplyffa/NPC indication |
Applies to the approved product and disease condition |
| Formulation or process patents |
Potentially separate |
Must be assessed independently from Patent 9,289,472 |
Patent expiration and orphan exclusivity are separate. Expiration of the patent would not automatically eliminate orphan exclusivity, and expiration of orphan exclusivity would not invalidate an unexpired patent.
What is the Orange Book status of arimoclomol?
Because Miplyffa is an FDA-approved small-molecule drug, its approved product and listed patents are evaluated through the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[4]
The practical Orange Book questions are:
- Whether U.S. Patent 9,289,472 is listed for Miplyffa.
- Whether the listing is directed to the approved NPC use.
- Whether the FDA has assigned a patent-use code.
- Whether additional arimoclomol patents have later expiration dates.
- Whether a future ANDA applicant must make a Paragraph IV certification.
The supplied claims strongly align with the approved arimoclomol-plus-miglustat NPC therapy. That alignment makes the patent a candidate for method-of-use listing, but the patent’s actual Orange Book listing status must be determined from the current FDA Orange Book patent table, not from the claim text alone.[4]
What Paragraph IV challenges and generic entry risks exist?
An ANDA applicant seeking approval before expiration of a listed patent could submit a Paragraph IV certification asserting that the patent is invalid, unenforceable, or not infringed.[5]
For this patent, potential challenge positions would include:
Non-infringement
A generic applicant could argue that:
- Its product is not a hydroxylamine derivative.
- Its product does not amplify Hsp70 gene expression.
- Its label does not induce use for a claimed lysosomal storage disease.
- It does not promote combination use with miglustat or another listed treatment.
- The approved indication falls outside a properly construed claim limitation.
Invalidity
Potential invalidity theories could include:
- Anticipation based on earlier disclosure of arimoclomol for lysosomal storage disease.
- Obviousness based on combining known Hsp70-inducing compounds with known lysosomal disease treatments.
- Lack of written description for the full class of hydroxylamine derivatives or all listed diseases.
- Lack of enablement for the broad functional mechanism.
- Indefiniteness involving “capable of increasing,” “amplifying,” or “structural analogue.”
The strongest commercial claims are likely claims 6, 9, 10 and 12 because they can be mapped to the approved product, NPC indication and miglustat combination. Broad claim 1 may have greater theoretical scope but may face a more substantial validity challenge.
Which companies are challenging arimoclomol patent rights?
The relevant commercial parties are:
| Company |
Role |
| Orphazyme A/S |
Original developer and historical patent holder associated with arimoclomol |
| Zevra Therapeutics |
Current commercial sponsor of Miplyffa in the United States |
| Generic manufacturers |
Potential ANDA applicants after or during listed-patent protection |
| Academic and rare-disease developers |
Potential users of the Hsp70 therapeutic approach in other lysosomal diseases |
No Paragraph IV litigation or settlement can be attributed to this patent from the claim text supplied. A litigation conclusion requires review of FDA patent listings, ANDA notices, district-court dockets and any Federal Circuit proceedings.
How strong is the patent estate?
The patent estate is strongest where the accused use closely follows the approved Miplyffa therapy:
- Arimoclomol is the active agent.
- NPC is the treated disease.
- Miglustat is used as combination therapy.
- Hsp70 induction is part of the disclosed pharmacological rationale.
The estate is weaker against products that use a different mechanism, a different compound class, or a different lysosomal disease without a label or evidence tying the use to the claimed Hsp70 mechanism.
Strength assessment
| Factor |
Assessment |
| Product coverage |
Strong for arimoclomol under claim 6 |
| Indication coverage |
Strong for NPC under claim 9 |
| Combination coverage |
Stronger where miglustat is used |
| Chemical composition protection |
Not provided by the supplied claims |
| Formulation protection |
Not provided by the supplied claims |
| Mechanism limitation |
Creates a non-infringement and validity issue |
| Disease breadth |
Commercially valuable but vulnerable to enablement and written-description attacks |
| Biosimilar protection |
Not applicable because arimoclomol is a small molecule |
Does biosimilar risk apply to arimoclomol?
No. Arimoclomol is a small-molecule drug, so competitive entry would proceed through the ANDA pathway rather than the biosimilar pathway under the Biologics Price Competition and Innovation Act.[5]
The relevant risks are:
- ANDA filing after or during Orange Book patent protection.
- Paragraph IV litigation.
- Carve-out of patented method-of-use language.
- Labeling that omits the patented combination or indication.
- Post-expiration launch.
- Off-label use that creates inducement concerns.
A generic company may seek approval for a label that omits a patented use, but the commercial value of such a strategy depends on whether the remaining label supports meaningful sales.
What manufacturing and geographic barriers exist?
U.S. Patent 9,289,472 does not, based on the supplied claims, claim manufacturing steps, intermediates, polymorphs, salts, analytical specifications, or delivery devices. It therefore creates a use-based barrier rather than a manufacturing barrier.
Geographically, the patent is limited to the United States. Corresponding protection in Europe, Japan, China and other markets would depend on the relevant national members of the patent family, national prosecution, opposition outcomes, term adjustments and maintenance payments.
A global freedom-to-operate review should separate:
- U.S. method-of-use rights
- Foreign national equivalents
- Arimoclomol composition rights
- Formulation and dosage patents
- Manufacturing-process patents
- Regulatory exclusivity
- Orphan-designation protection
Key Takeaways
- U.S. Patent 9,289,472 is a method-of-treatment patent, not a composition or formulation patent.
- Claim 1 broadly covers hydroxylamine derivatives that increase intracellular Hsp70 through amplified Hsp70 gene expression.
- Claim 6 directly targets arimoclomol.
- Claim 9 covers Niemann-Pick disease types A, B, C and D.
- Claims 10 and 12 are commercially important for arimoclomol used with miglustat or other listed therapies.
- Miplyffa’s FDA-approved NPC use closely aligns with the patent’s arimoclomol, NPC and combination-therapy claims.
- Arimoclomol is subject to ANDA and Paragraph IV risk, not biosimilar competition.
- The broadest litigation vulnerabilities are likely to involve mechanism, enablement, written description, obviousness and the interpretation of “capable of increasing” Hsp70.
- The patent does not, on the supplied claim set, establish protection for arimoclomol’s chemical composition, formulation or manufacturing process.
- Patent expiration, Orange Book listing and any Paragraph IV litigation must be assessed from current USPTO, FDA and court records.
FAQs About U.S. Patent 9,289,472
Does U.S. Patent 9,289,472 claim arimoclomol itself?
No. The patent claims methods of using arimoclomol and related hydroxylamine derivatives. It does not claim the arimoclomol molecule as a composition of matter in the supplied claims.
Does the patent cover Niemann-Pick disease type C?
Yes. Claim 9 expressly includes Niemann-Pick disease type C, subject to all limitations inherited from claims 8 and 1.
Does miglustat fall within the patent claims?
Yes, miglustat is expressly listed in claim 12 and is also relevant to the broader combination-treatment language in claim 10.
Can a generic manufacturer avoid the patent by omitting Hsp70 from its label?
Potentially, but label language alone is not determinative. Promotional conduct, product instructions, clinical materials and the objectively intended use could affect an inducement analysis.
Is Miplyffa protected by orphan-drug exclusivity as well as patents?
Yes. FDA orphan-drug exclusivity is separate from patent protection and applies to the approved arimoclomol indication for the statutory exclusivity period.[2][3]
References
- United States Patent and Trademark Office. (2016). U.S. Patent No. 9,289,472, Treatment of lysosomal storage diseases.
- U.S. Food and Drug Administration. (2024, September 20). FDA approves first treatment for Niemann-Pick disease type C.
- U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and Paragraph IV certifications.
